10X Genomics Earnings Estimate

TXG Stock  USD 15.30  0.99  6.92%   
By analyzing 10X Genomics' earnings estimates, investors can diagnose different trends across 10X Genomics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for 10X Genomics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
10X Genomics is projected to generate -0.165825 in earnings per share on the 31st of December 2024. 10X Genomics earnings estimates module stress-tests analyst consensus about projected 10X Genomics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as 10X Genomics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

10X Genomics Revenue Breakdown by Earning Segment

By analyzing 10X Genomics' earnings estimates, investors can diagnose different trends across 10X Genomics' analyst sentiment over time as well as compare current estimates against different timeframes. The 10X Genomics' current Gross Profit Margin is estimated to increase to 0.86, while Gross Profit is projected to decrease to roughly 286.8 M.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

10X Genomics Earnings per Share Projection vs Actual

About 10X Genomics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of 10X Genomics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current 10X Genomics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as 10X Genomics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-1.3 B-1.2 B
Retained Earnings Total Equity-926.4 M-880.1 M
Earnings Yield(0.04)(0.04)
Price Earnings Ratio(25.70)(26.99)
Price Earnings To Growth Ratio(0.52)(0.50)

Currently Active Assets on Macroaxis

When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
5.261
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.11)
Return On Equity
(0.25)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.